Patents by Inventor Akihiko Takashima
Akihiko Takashima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240013798Abstract: A conversion device (10) includes: an evaluation unit (11) that estimates which one of subjective evaluation values obtained by quantifying easiness of transmission of a content of a voice felt by a person is to be taken from an input voice signal; and a conversion unit (12) that converts the input voice signal so as to obtain a subjective evaluation value of a predetermined value on the basis of the subjective evaluation value estimated by the evaluation unit (11).Type: ApplicationFiled: November 13, 2020Publication date: January 11, 2024Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Kazunori YAMADA, Ko MITSUDA, Tetsuya KINEBUCHI, Yushi AONO, Hiroko YABUSHITA, Akihiko TAKASHIMA, Takashi NAKAMURA
-
Publication number: 20220406093Abstract: A facial expression label is assigned to face image data of a person with high accuracy. A facial expression data set storage unit (110) stores a facial expression data set in which the facial expression label is assigned to the face images in which people belonging to various groups show various facial expressions. A facial expression sampling unit (11) acquires a face image in which a person belonging to the desired group shows a desired facial expression. A representative feature quantity calculation unit (12) determines a representative feature quantity for each facial expression label from the face image of the desired group. The target data extraction unit (13) extracts target data from a facial expression data set. A target feature quantity calculation unit (14) calculates a target feature quantity from the target data.Type: ApplicationFiled: November 19, 2019Publication date: December 22, 2022Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Akihiko TAKASHIMA, Ryo MASUMURA
-
Publication number: 20220172383Abstract: A weight mask generation device includes: a displacement amount derivation unit that derives displacement amounts of feature points in an entire region of a face shape; a separation unit that derives separated displacement amounts, each of which is a displacement amount of each feature point for every deformation pattern of a partial region of the face shape, based on the displacement amounts of the feature points in the entire region of the face shape and deformation degrees for every deformation pattern of the partial regions of the face shape; a normalization unit that derives normalized and separated displacement amounts, which are obtained by normalizing the separated displacement amounts, for every deformation pattern of the partial regions of the face shape; and a weight value generation unit that generates weight values of the feature points in the entire region of the face shape based on the normalized and separated displacement amounts for every deformation pattern of the partial regions of the faceType: ApplicationFiled: March 11, 2020Publication date: June 2, 2022Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Akihiko TAKASHIMA, Masaaki MATSUMURA, Hajime NOTO, Hideaki KIMATA
-
Publication number: 20210393551Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: September 1, 2021Publication date: December 23, 2021Inventors: Akihiko TAKASHIMA, Yoshiyuki SOEDA, Hiroyuki OSADA, Yasuo IHARA, Tomohiro MIYASAKA, Hachiro SUGIMOTO
-
Publication number: 20180161288Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: February 12, 2018Publication date: June 14, 2018Inventors: Akihiko TAKASHIMA, Yoshiyuki SOEDA, Hiroyuki OSADA, Yasuo IHARA, Tomohiro MIYASAKA, Hachiro SUGIMOTO
-
Patent number: 9907799Abstract: A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).Type: GrantFiled: April 2, 2014Date of Patent: March 6, 2018Assignees: THE DOSHISHA, National Center for Geriatrics and GerontologyInventors: Tomohiro Miyasaka, Hachiro Sugimoto, Rie Tokizane, Yuki Shinzaki, Yohei Oe, Tetsuo Ota, Akihiko Takashima, Yoshiyuki Soeda, Yasuo Ihara, Yoshikazu Inoue
-
Publication number: 20160030437Abstract: A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).Type: ApplicationFiled: April 2, 2014Publication date: February 4, 2016Inventors: Tomohiro Miyasaka, Hachiro Sugimoto, Rie Tokizane, Yuki Shinzaki, Yohei Oe, Tetsuo Ota, Akihiko Takashima, Yoshiyuki Soeda, Yasuo Ihara, Yoshikazu Inoue
-
Publication number: 20140249180Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: October 3, 2012Publication date: September 4, 2014Applicants: National Center for Geriatrics and Gerontology, THE DOSHISHAInventors: Akihiko Takashima, Yoshiyuki Soeda, Hiroyuki Nagata, Yasuo Ihara, Tomohiro Miyasaka, Hachiro Sugimoto
-
Patent number: 7135610Abstract: A transgenic mouse transformed with a DNA encoding a mutant human tau protein, wherein the mouse exhibits neurofibrillary tangles in its brain. The transgenic mouse is useful for the development of the agent for treating neurodegenerative disorders such as Alzheimer's disease.Type: GrantFiled: June 14, 2001Date of Patent: November 14, 2006Assignee: RikenInventor: Akihiko Takashima
-
Publication number: 20050034182Abstract: A transgenic mouse transformed with a DNA encoding a mutant human tau protein, wherein the mouse exhibits neurofibrillary tangles in its brain. The transgenic mouse is useful for the development of the agent for treating neurodegenerative disorders such as Alzheimer's disease.Type: ApplicationFiled: June 14, 2001Publication date: February 10, 2005Inventor: Akihiko Takashima
-
Publication number: 20020058637Abstract: A preventive or therapeutic agent for Arzheimer's disease which comprises a substance exhibiting an inhibitory action to tau-protein kinase I as an effective component is provided. A pharmaceutical composition comprising said agent and a method of inhibiting neuronal cell death in the brain are also provided.Type: ApplicationFiled: May 30, 2001Publication date: May 16, 2002Inventors: Akihiko Takashima, Toshimitsu Hoshino, Kazutomo Imahori, Ken-Ichi Saito, Akiko Shiratsuchi, Showbu Sato
-
Patent number: 6248559Abstract: A preventive or therapeutic agent for Alzheimer's disease which comprises a substance exhibiting an inhibitory action to tau-protein kinase I as an effective component is provided. A pharmaceutical composition comprising said agent and a method of inhibiting neuronal cell death in the brain are also provided.Type: GrantFiled: December 21, 1998Date of Patent: June 19, 2001Assignee: Mitsubishi Chemical CorporationInventors: Akihiko Takashima, Toshimitsu Hoshino, Kazutomo Imahori, Ken-ichi Saito, Akiko Shiratsuchi, Showbu Sato
-
Patent number: 6071694Abstract: A preventive or therapeutic agent for Alzheimer's disease which comprises a substance exhibiting an inhibitory action to tau-protein kinase I as an effective component is provided. A pharmaceutical composition comprising said agent and a method of inhibiting neuronal cell death in the brain are also provided.Type: GrantFiled: June 5, 1995Date of Patent: June 6, 2000Assignee: Mitsubishi Chemical CorporationInventors: Akihiko Takashima, Toshimitsu Hoshino, Kazutomo Imahori, Ken-ichi Saito, Akiko Shiratsuchi, Showbu Sato
-
Patent number: 5837853Abstract: A preventive or therapeutic agent for Alzheimer's disease which comprises a substance exhibiting an inhibitory action to tau-protein kinase I as an effective component is provided. A pharmaceutical composition comprising said agent and a method of inhibiting neuronal cell death in the brain are also provided.Type: GrantFiled: February 20, 1996Date of Patent: November 17, 1998Assignee: Mitsubishi Chemical CorporationInventors: Akihiko Takashima, Toshimitsu Hoshino, Kazutomo Imahori, Ken-ichi Saito, Akiko Shiratsuchi, Showbu Sato